Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial

Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversità Vita-Salute San Raffaele

About this trial

In metastatic NSCLC patients with PD-L1 expression ≥50%, a circulating immature (CD10-) LDNs level of ≥30.5% confers a high risk of hyperprogression (HPD) with first line single-agent immune-checkpoint inhibitors (SA-ICI). HPD is defined as a tumor growth rate (TGR) delta ≥50% between pre-treatment and post-treatment, and/or a TGR ratio ≥2. The combination of platinum-based chemotherapy (PCT) with ICI in this setting could prevent the occurrence of HPD and ultimately improve survival outcomes.

This randomized, multicentric, open-label, phase 2 trial will include patients with stage IV NSCL, without targetable oncogene drivers, PD-L1 TPS≥50%, and measurable disease on two CT scans performed before randomization. Participants will be randomized 1:1 to SA-ICI or ICI+PCT. Radiological evaluation will be performed by CT-scan at 6-8 weeks and subsequently according to the local investigators' schedule.

In the SA-ICI arm, ICI regimen will include cemiplimab. In the PCT+ICI arm, PCT regimens will include both carboplatin or cisplatin + pemetrexed (for non-squamous histology) or paclitaxel (for squamous histology) in combination with cemiplimab.

PCT will be administered for three cycles. In case of stable disease or partial response according to RECIST v.1.1, cemiplimab will be performed as monotherapy from the third cycle until disease progression or unacceptable toxicity. If progression according to RECIST v.1.1 or HPD after three cycles of PCT+ICI, patients will be treated with standard second line therapy as local standard of care.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

The participant (or legally acceptable representative) has provided documented informed consent to participation to the study and data protection consent form.

Male or female aged 18 years or older.

ECOG Performance Status of 0 - 2.

Pathologically (histologically or cytologically) confirmed diagnosis of stage IV NSCLC (TNM 8th edition), who received no prior systemic treatment for recurrent or metastatic NSCLC. Mixed squamous/non-squamous tumors are eligible.

Disqualifiers

Any infection requiring hospitalization or treatment with IV anti-infectives within 2 weeks of first dose of study medication

Known uncontrolled infection with HIV, hepatitis B or hepatitis C infection, diagnosis of immunodeficiency, and/or tuberculosis (active or latent). No serological testing is required unless mandated by local health authority.

Administration of live or live-attenuated vaccines within 30 days before the baseline LDNs assessment. Administration of killed vaccines is allowed. Receipt of COVID-19 vaccination within 1 week of planned start of study medication or for which the planned COVID-19 vaccinations would not be completed 1 week prior to start of study medication.

History of interstitial lung disease (eg, idiopathic pulmonary fibrosis or organizing pneumonia), of active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management.

Trial design

Design model

Parallel

Treatments tested in this trial

  • chemotherapy plus cemiplimab

    Combination product

    Combination of platinum-based chemotherapy (PCT) with ICI. PCT regimens will include both carboplatin or cisplatin plus pemetrexed (for non-squamous histology) or paclitaxel (for squamous histology) in combination with cemiplimab. PCT will be administered for three cycles.

  • Cemiplimab

    Drug

    single-agent immune-checkpoint inhibitors

Treatment groups

74 Participants
are divided into 2 treatment groups
Group A: single-agent immune-checkpoint inhibitorsActive comparator 1 intervention
Group B: PCT regimens + immune-checkpoint inhibitorsExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

HPD rate

HPD rate, defined as the proportion of patients with a delta of TGR ≥50% or a TGR ratio ≥2 at 7 weeks ± 5 days from randomization

Time frame
up to HPD, end of treatment for a maximum of 108 weeks whichever comes first
2

ED rate

ED rate: who died without undergoing a scan after treatment initiation.

Time frame
up to ED, end of treatment for a maximum of 108 weeks whichever comes first

Secondary outcomes

1

Overall survival (OS)

To compare the activity of cemiplimab+PCT relative to cemiplimab alone.

Time frame
up to HPD, ED, end of treatment for a maximum of 108 weeks whichever comes first
2

Progression free survival (PFS)

To compare the activity and efficacy of cemiplimab+PCT relative to cemiplimab alone

Time frame
up to HPD, ED, end of treatment for a maximum of 108 weeks whichever comes first
3

Objective response rate (ORR)

To compare the activity of cemiplimab+PCT relative to cemiplimab alone.

Time frame
up to HPD, ED, end of treatment for a maximum of 108 weeks whichever comes first
4

Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

Summary of adverse events (AE), with a focus on TRAEs coded based upon the Medical Dictionary for Regulatory Activities (MedDRA) and graded based upon CTCAE, ver. 5.0.

Time frame
up to 90 days after the last dose of study treatment

Other outcomes

1

Exploratory baseline and dynamic characterization of patients' tissue and circulating clinical and radiological features correlated with HPD occurrence, according to treatment arm

To characterize how treatments with cemiplimab alone and cemiplimab+PCT modulate circulating or tissue features of HPD, clinical, radiological, and biological

Time frame
through study completion, an avarage of 3 years
2

Exploratory characterization of clinical, radiological, and biological patients' features correlated with HPD occurrence.

To characterize how treatments with cemiplimab alone and cemiplimab+PCT modulate circulating or tissue features of HPD

Time frame
through study completion, an avarage of 3 years
3

HPD rate among patients not meeting inclusion criterion 7

To characterize HPD rate among patients not meeting inclusion criterion 7 (circulating CD10- LDNs \>30.5% at screening).

Time frame
through study completion, an avarage of 3 years

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Università Vita-Salute San Raffaele

Lead sponsor

Istituto Di Ricerche Farmacologiche Mario Negri

Collaborator

This trial is not recruiting at the moment. You can still explore other options: